RECOMBINANT HUMAN GROWTH-HORMONE IN INFANTS AND YOUNG-CHILDREN WITH CHRONIC RENAL-INSUFFICIENCY

被引：43

作者：

FINE, RN

ATTIE, KM

KUNTZE, J

BROWN, DF

KOHAUT, EC

机构：

[1] Department of Pediatrics, State University of New York at Stony Brook, Stony Brook, 11794-8111, NY

[2] Department of Medical Affairs, Genentech, Inc., South San Francisco, California

[3] Department of Pediatric Nephrology, University of Alabama School of Medicine, Birmingham, Alabama

来源：

PEDIATRIC NEPHROLOGY | 1995年 / 9卷 / 04期

关键词：

RECOMBINANT HUMAN GROWTH HORMONE; CHRONIC RENAL INSUFFICIENCY; CHILDREN UNDER 2.5 YEARS;

D O I：

10.1007/BF00866726

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Children with chronic renal insufficiency (CRI) secondary to congenital structural abnormalities frequently have significant growth retardation by 2 years of age. In a multicenter placebo-controlled study of the use of recombinant human growth hormone (rhGH), 30 of 125 (24%) participants were < 2.5 years of age at enrollment, Since the treatment arms of the study were balanced for age at randomization, data for these patients were examined for efficacy and safety. During the first 2 years of the study, approximately two-thirds of the patients (n = 19) received rhGH 0.05 mg/kg per day subcutaneously and one-third (n = 11) received placebo injections, At entry into the study, the mean (+/- SD) calculated creatinine clearance was 29.2 +/- 14.3 (range 12.0 - 63.7) ml/min per 1.73 m(2) in the rhGH-treated group and 23.3 +/- 15.1 (range 8.0 - 59.4) ml/min per 1.73 m(2) in the placebo-treated group, The 1st year growth rate was 14.1 +/- 2.6 cm/year for the rhGH-treated group and 9.3 +/- 1.5 cm/year in the placebo-treated group (P < 0.00005). During the 2nd year of the study, the growth rate was 8.6 +/- 1.2 cm/year in the rhGH-treated group compared with 6.9 +/- 1.0 in the placebo group (P = 0.025). The Delta height standard deviation score was +2.0 +/- 0.7 for the rhGH-treated group compared with -0.2 +/- 1.1 in the placebo-treated group (P < 0.00005) during the 2 years of the study. Minor adverse events occurred with similar frequency in both groups. These data suggest that rhGH is efficacious and safe in children with CRI under age 2.5 years. rhGH therapy may correct significant loss of growth at this age when used in conjunction with optimal medical management.

引用

页码：451 / 457

页数：7

共 25 条

[1]

Abithol C.L., Zilleruelo G., Montane B., Strauss J., Growth of uremic infants on forced feeding regimens, Pediatr Nephrol, 7, pp. 173-177, (1993)

[2]

Linne T., Bang P., Karlsson E., Ritzen M., Recombinant human growth hormone treatment gives improved growth also in uremic children below two years of age, Pediatr Nephrol, 6, (1992)

[3]

Tonshoff B., Tonshoff C., Mehls O., Pinkowski J., Blum W.F., Heinrick V., Stover B., Gretz N., Growth hormone treatment in children with preterminal chronic renal failure: no adverse effect on glomerular filtration rate, Eur J Pediatr, 151, pp. 601-607, (1992)

[4]

Lippe B., Fine R.N., Koch V.H., Sherman B.M., Accelerated growth following treatment of children with chronic renal failure with recombinant human growth hormone (Somatrem): a preliminary report, Acta Paediatr Scand, 343, pp. S127-S131, (1988)

[5]

Koch V.H., Lippe B.M., Nelson P.A., Boechat M.I., Sherman B.M., Fine R.N., Accelerated growth after recombinant human growth hormone treatment of children with chronic renal failure, J Pediatr, 115, pp. 356-371, (1989)

[6]

Tonshoff B., Mehls O., Heinrich U., Blum W.F., Rank M.B., Schaver A., Growth-stimulating effects of recombinant human growth hormone in children with end-stage renal disease, J Pediatr, 16, pp. 561-566, (1990)

[7]

Rees L., Rigden S.P.A., Ward G., Preece M.A., Treatment of short stature in renal disease with recombinant human growth hormone, Arch Dis Child, 65, pp. 856-860, (1990)

[8]

Johansson G., Sietnieke A., Janssens F., Proesmans W., Van-derschueren-Lodeweyckx M., Holmberg C., Sipila I., Broyer M., Rappaport R., Albertsson-Wikland K., Berg U., Jodal U., Rees L., Rigden S.P.A., Preece M.A., Recombinant human growth treatment in short children with chronic renal disease, before transplantation or with functioning renal transplant: an interim report on five European studies, Acta Paediatr Scand, 370, pp. 36-42, (1990)

[9]

Tonshoff B., Dietz M., Haffner D., Tonshoff C., Stover B., Mehls O., Acta Paediatr Scand, 379, pp. S33-S41, (1991)

[10]

Van Es A., Growth hormone treatment in short children with chronic renal failure and after renal transplantation: combined data from European clinical trials, Acta Paediatr Scand, 379, pp. S42-S48, (1991)

← 1 2 3 →